March 2009 PBAC Outcomes - Reviews

DRUG AND FORM	DRUG USE AND TYPE	REASON FOR REVIEW	PBAC FINDING
CLOPIDOGREL HYDROGEN SULFATE, tablet, 75 mg (base), Iscover^®, Bristol-Myers Squibb Pharmaceuticals; Plavix^®, Sanofi-Aventis Australia Pty Ltd Review	Anti-platelet	To review the cost-effectiveness of clopidogrel in coronary artery stenting.	The PBAC recommended extending the listing of clopidogrel for use following stent insertion in patients without a prior history of Acute Coronary Syndrome (ACS) in combination with aspirin, and as monotherapy in those patients unable to tolerate aspirin. The PBAC considered that there is evidence that this is best clinical practice and noted that any increase in use is likely to be minimal following this listing.

Department of Health and Aged Care